Correlation Between Protagonist Therapeutics and Veracyte

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Protagonist Therapeutics and Veracyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protagonist Therapeutics and Veracyte into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Protagonist Therapeutics and Veracyte, you can compare the effects of market volatilities on Protagonist Therapeutics and Veracyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protagonist Therapeutics with a short position of Veracyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protagonist Therapeutics and Veracyte.

Diversification Opportunities for Protagonist Therapeutics and Veracyte

ProtagonistVeracyteDiversified AwayProtagonistVeracyteDiversified Away100%
-0.63
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Protagonist and Veracyte is -0.63. Overlapping area represents the amount of risk that can be diversified away by holding Protagonist Therapeutics and Veracyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Veracyte and Protagonist Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protagonist Therapeutics are associated (or correlated) with Veracyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Veracyte has no effect on the direction of Protagonist Therapeutics i.e., Protagonist Therapeutics and Veracyte go up and down completely randomly.

Pair Corralation between Protagonist Therapeutics and Veracyte

Given the investment horizon of 90 days Protagonist Therapeutics is expected to generate 3.92 times less return on investment than Veracyte. In addition to that, Protagonist Therapeutics is 1.26 times more volatile than Veracyte. It trades about 0.03 of its total potential returns per unit of risk. Veracyte is currently generating about 0.13 per unit of volatility. If you would invest  3,671  in Veracyte on September 19, 2024 and sell it today you would earn a total of  282.00  from holding Veracyte or generate 7.68% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy95.45%
ValuesDaily Returns

Protagonist Therapeutics  vs.  Veracyte

 Performance 
JavaScript chart by amCharts 3.21.15OctNovDec -100102030
JavaScript chart by amCharts 3.21.15PTGX VCYT
       Timeline  
Protagonist Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Protagonist Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's technical and fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
JavaScript chart by amCharts 3.21.15OctNovDecNovDec3436384042444648
Veracyte 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Veracyte are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Veracyte unveiled solid returns over the last few months and may actually be approaching a breakup point.
JavaScript chart by amCharts 3.21.15OctNovDecNovDec3234363840424446

Protagonist Therapeutics and Veracyte Volatility Contrast

   Predicted Return Density   
JavaScript chart by amCharts 3.21.15-4.41-3.31-2.2-1.09-0.01741.012.053.14.145.18 0.0400.0450.0500.0550.060
JavaScript chart by amCharts 3.21.15PTGX VCYT
       Returns  

Pair Trading with Protagonist Therapeutics and Veracyte

The main advantage of trading using opposite Protagonist Therapeutics and Veracyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protagonist Therapeutics position performs unexpectedly, Veracyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Veracyte will offset losses from the drop in Veracyte's long position.
The idea behind Protagonist Therapeutics and Veracyte pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Other Complementary Tools

Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Stocks Directory
Find actively traded stocks across global markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum